Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®).
| Website | http://www.skyebioscience.com |
| Employees | 17 (11 on RocketReach) |
| Founded | 2011 |
| Address | 12250 El Camino Real Drive Suite 100, San Diego, California 92130, US |
| Industry | Biotechnology Research |
| Competitors | Zynerba Pharmaceuticals, Canopy Growth Corporation, MedMen, Curaleaf, Charlotte's Web, Green Thumb Industries (GTI), CV Sciences, Inc., Trulieve, Dixie Brands, Inc., Verano +27 more (view full list) |
Looking for a particular Skye Bioscience Inc. employee's phone or email?
Skye Bioscience Inc. Questions
Chris Twitty is the Chief Scientific Officer of Skye Bioscience Inc..
11 people are employed at Skye Bioscience Inc..
Skye Bioscience Inc. is based in San Diego, California.
Top Skye Bioscience Inc. Employees
-
Chris Twitty
Chief Scientific Officer at Skye Bioscience Inc.
San Diego, CA, US24 -
5+5+
-
13 -
25
-
25+
-
Lisa Situ
Sr Accounting Manager at Skye Bioscience Inc.
San Francisco, CA, US21
